Phase 1 study of an AKT-inhibitor (MK-2206) combined with lapatinib in adult solid tumors followed by dose-expansion in advanced HER2+ breast cancer

類似資料

• Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
  著者:: Lubet, Ronald A., 等
  出版事項: (2018)
• Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
  著者:: Lubet, Ronald A., 等
  出版事項: (2019)
• Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer
  著者:: Rampurwala, Murtuza, 等
  出版事項: (2016)
• Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
  著者:: Sangai, Takafumi, 等
  出版事項: (2012)
• A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer
  著者:: Ma, Cynthia X., 等
  出版事項: (2017)